These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31286139)

  • 1. Association of gout medications and risk of cataract: a population-based case-control study.
    Li YJ; Perng WT; Tseng KY; Wang YH; Wei JC
    QJM; 2019 Nov; 112(11):841-846. PubMed ID: 31286139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
    Chang HW; Lin YW; Lin MH; Lan YC; Wang RY
    PLoS One; 2019; 14(1):e0210085. PubMed ID: 30615649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
    Lin HC; Daimon M; Wang CH; Ho Y; Uang YS; Chiang SJ; Wang LH
    Int J Cardiol; 2017 Apr; 233():85-90. PubMed ID: 28202260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opportunities for improving medication use and monitoring in gout.
    Singh JA; Hodges JS; Asch SM
    Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between colchicine use and the risk of dementia among patients with gout: A nationwide retrospective cohort study.
    Chen PY; Tseng CC; Lee YT; Yip HT; Chang R; Wei JC
    Int J Rheum Dis; 2024 May; 27(5):e15162. PubMed ID: 38720421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure to allopurinol and the risk of cataract extraction in elderly patients.
    Garbe E; Suissa S; LeLorier J
    Arch Ophthalmol; 1998 Dec; 116(12):1652-6. PubMed ID: 9869797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resolution of massive tophaceous gout with three urate-lowering drugs.
    Mejía-Chew C; Torres RJ; de Miguel E; Puig JG
    Am J Med; 2013 Nov; 126(11):e9-10. PubMed ID: 23978312
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout.
    Kang EH; Park EH; Shin A; Song JS; Kim SC
    Eur Heart J; 2021 Nov; 42(44):4578-4588. PubMed ID: 34508567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the association between colchicine therapy and serious adverse events.
    Todd BA; Billups SJ; Delate T; Canty KE; Kauffman AB; Rawlings JE; Wagner TM
    Pharmacotherapy; 2012 Nov; 32(11):974-80. PubMed ID: 23019065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
    Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
    Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of allopurinol on risk of myocardial infarction.
    Grimaldi-Bensouda L; Alpérovitch A; Aubrun E; Danchin N; Rossignol M; Abenhaim L; Richette P;
    Ann Rheum Dis; 2015 May; 74(5):836-42. PubMed ID: 24395556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hyperuricemia and gout--treatment].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypothyroidism on Colchimax revealed by restless legs syndrome.
    Bon E; Rolland Y; Laroche M; Cantagrel A; Mazières B
    Rev Rhum Engl Ed; 1996 Apr; 63(4):304. PubMed ID: 8738454
    [No Abstract]   [Full Text] [Related]  

  • 16. Colchicine in acute gout.
    Morris I; Varughese G; Mattingly P
    BMJ; 2003 Nov; 327(7426):1275-6. PubMed ID: 14644973
    [No Abstract]   [Full Text] [Related]  

  • 17. GOSPEL 2 - Colchicine for the treatment of gout flares in France - a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age.
    Pascart T; Lancrenon S; Lanz S; Delva C; Guggenbuhl P; Lambert C; Aubert JP; Saraux A; Ea HK; Lioté F
    Joint Bone Spine; 2016 Dec; 83(6):687-693. PubMed ID: 26919801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of gout and colorectal cancer in Taiwan: a nationwide population-based cohort study.
    Chuang JP; Lee JC; Leu TH; Hidajah AC; Chang YH; Li CY
    BMJ Open; 2019 Oct; 9(10):e028892. PubMed ID: 31601586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
    Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
    Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.